Trial intelligence / Profile preview

Lenbelintide in Obesity or Overweight (SELENE 1)

NCT07784725Phase 3Recruiting

Sponsor
AstraZeneca
Start
Aug 2026
Primary completion
Aug 2028
Countries
16
01

Overview

A Phase 3 trial of lenbelintide in obesity, sponsored by AstraZeneca. Started Aug 2026; status: recruiting.

02

Drugs

lenbelintide
03

Conditions

obesity

Beyond the preview

Go deeper on NCT07784725.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07784725.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call